More Stories

Informist, Friday, Jan. 16, 2026

 

MUMBAI – Shares of pharmaceutical companies are expected to continue to be range-bound next week as investors turn their focus to the December quarter earnings. Investors will keenly await the Oct-Dec earnings to gauge volume and price trends amid concerns about negative earnings surprises by some companies in the reporting quarter.

 

Among specific companies, Cipla's shares may face volatility amid supply disruptions to its Lanreotide drug, as its partner faces regulatory issues. 

 

The Nifty Pharma index has been in a consolidation phase for more than a year, and technical analysts expect this trend to continue in the near term. For the week ended Friday, the Nifty Pharma index closed 2.4% lower at 22217.05 points. The index is seen facing resistance at 22700-22750 points and support at 22100-21900 points, Jatin Gedia, technical research analyst at Motilal Oswal, said.

 

"Overall, I expect more negative surprises than positive ones in December quarter earnings for pharmaceutical companies," Vishal Manchanda, senior vice president, covering pharmaceutical markets at Systematix Group, said. The analyst expects wholesalers to defer purchases of generic Revlimid drugs until the exclusivity on these drugs expires. Product launches by pharmaceutical majors, which were keenly watched, have not yet hit the markets, adding uncertainty about growth prospects for companies such as Sun Pharmaceutical Industries and Dr. Reddy's Laboratories, the analyst said. However, Lupin is expected to outperform its peers in the reporting quarter, Manchanda added.

 

Cipla's performance is expected to be hit after its European contract manufacturing organisation partner, Pharmathen, temporarily paused production of the Lanreotide drug for remediation efforts. The supply disruption, along with more competition in the generic Advair drug and the expiry of generic Revlimid exclusivity, is expected to pose an earnings risk for the pharmaceutical company in 2026-27 (Apr-Mar), according to a research report by global brokerage Nomura. The brokerage has cut its estimate for the company's Lanreotide revenue to $50 million from around $150 million for FY27 and $5 million from $35 million for the March quarter. Generic Revlimid sales provided strong margin-accretive benefits for the company, while the expiry of shared Revlimid exclusivity would materially erode Cipla's margin performance, according to the brokerage.

 

Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries are expected to report 13% year-on-year fall in their cumulative net profit during the quarter due to Revlimid-related impact. While US-focused companies may see weak sales, domestically oriented companies are expected to perform well, driven by strong traction in chronic therapy portfolios, a healthy rise in prescription-based sales, and a better pricing mix. Volume growth for domestic companies, however, is expected to be muted.

 

 

TOP HEADLINES

 

* Sun Pharma says co's UNLOXCYT drug now available for prescription in US
* Zydus Life receives final US FDA approval for eltrombopag tablets
* Biocon raises INR 41.5 bln via QIP; SBI MF, ICICI Pru MF top investors
* Lanreotide production paused as supply partner facing US FDA check - Cipla
* Dr Reddy's launches OTC olopatadine hydrochloride ophthalmic solution in US
* Delhi HC upholds ban on 2 fixed dose combinations for type-II diabetes cure
* Zydus Life arm gets US FDA nod for Zycubo, a first for children with Menkes
* Earnings Outlook: Dr Reddy's Q3 earnings seen hit; Revlimid effect fades out
* Biocon sets QIP floor price at INR 387.74 per shr, issue opens Mon
* IPO Alert: Rodec Pharma files DRHP with SEBI for OFS of 5.65 mln shares
* Alembic Pharma gets tentative US FDA approval for Bosutinib tablets
* HC allows Zydus Lifesciences to manufacture, sell biosimilar of Nivolumab
* Earnings Outlook:India, non-US mkts to drive modest Q3 growth for pharma cos
* US FDA approves Biocon arm's ANDA for Everolimus tablets for oral suspension
* Dr Reddy's Hyderabad facility gets US FDA post-application action letter
* Aurobindo Pharma arm gets nod from Health Canada for Dyrupeg biosimilar drug

 

The following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	27755.00	(-)1.20	28325.00	27365.00
Alkem Laboratories	5836.50	0.70	5920.50	5754.50
Aurobindo Pharma	1172.70	(-)2.20	1207.40	1149.00
Biocon	377.65	(-)0.50	389.90	368.40
Cipla	1397.50	(-)4.70	1433.70	1349.10
Divi's Laboratories	6236.00	(-)5.80	6439.00	6126.00
Dr Reddy's Laboratories	1175.50	(-)2.90	1206.80	1155.80
Gland Pharma	1704.20	1.40	1786.50	1654.90
GlaxoSmithKline Pharmaceuticals	2345.40	(-)1.10	2434.90	2295.30
Glenmark Pharmaceuticals	2000.70	(-)0.30	2044.20	1968.20
Granules India	583.10	(-)3.10	611.70	563.70
Ipca Laboratories	1509.90	(-)4.10	1539.00	1467.20
Laurus Labs	1076.80	(-)0.60	1107.90	1054.90
Lupin	2177.90	(-)0.20	2233.80	2145.00
Natco Pharma	859.40	(-)3.50	908.30	828.50
Pfizer	4760.90	(-)2.30	4876.20	4684.80
Sanofi India	4164.00	1.00	4290.90	3958.10
Sun Pharmaceutical Industries	1668.90	(-)3.50	1727.40	1630.00
Torrent Pharmaceuticals	4018.20	1.40	4067.40	3947.40
Zydus Lifesciences	868.10	(-)3.00	900.40	849.20
Nifty Pharma	22217.05	(-)2.40	22601.40	21983.10
Nifty 50	25694.35	0.00	25954.50	25532.30
S&P Bse Sensex	83570.35	(-)0.00	84399.10	83042.10

 

End

 

US$1 = INR 90.87

 

Reported by Eshitva Prakash

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.